Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS20050233351 A1
Publication typeApplication
Application numberUS 11/011,438
Publication date20 Oct 2005
Filing date15 Dec 2004
Priority date16 Jun 1995
Also published asCA2224674A1, CA2224674C, DE69614539D1, DE69614539T2, EP0832431A1, EP0832431B1, US6878515, WO1997000446A1
Publication number011438, 11011438, US 2005/0233351 A1, US 2005/233351 A1, US 20050233351 A1, US 20050233351A1, US 2005233351 A1, US 2005233351A1, US-A1-20050233351, US-A1-2005233351, US2005/0233351A1, US2005/233351A1, US20050233351 A1, US20050233351A1, US2005233351 A1, US2005233351A1
InventorsUlf Landegren
Original AssigneeUlf Landegren
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Ultrasensitive immunoassays
US 20050233351 A1
The present invention relates to an immunological test kit and immunoassay using a first immobilized antibody having affinity for a specific antigen. The invention is characterized by a second and third antibody being specific for different determinants of the antigen and modified with cross-linkable oligonucleotides. For detection, the oligonucleotides are amplified, whereby only such oligonucleotides will be amplified which have been cross-linked to each other. In this way unspecific background is avoided and detection is possible down to single molecules.
Previous page
Next page
1. Reagents for use in an assay for detection of a macromolecule comprising two affinity reagents, each reagent being specific for a different determinant of said macromolecule, and each reagent having attached thereto an oligonucleotide which is conjugatable to the oligonucleotide attached to the other of said two reagents, wherein said oligonucleotides are conjugatable by means of ligation or hybridization to each other only when said affinity reagents have became bound to the same said macromolecule and wherein said conjugated oligonucleotides may then serve as a template for a nucleic acid amplification reaction, for detection of said macromolecule.
2. The reagents of claim 1, wherein said oligonucleotides conjugate through
i) hybridization of an oligonucleotide complementary to the conjugatable oligonucleotides;
ii) hybridization of the conjugatable oligonucleotides to each other; or
iii) ligation of the oligonucleotides.
3. The reagents of claim 1, wherein said macromolecule is a protein.
4. The reagents according to claim 1, wherein the reagents are antibodies.
5. The reagents of claim 1, wherein said reagents are polyclonal antibodies, monoclonal antibodies or single chain antibodies.
6. The reagents according to claim 1, wherein the oligonucleotides are complementary to each other.
7. The reagents of claim 1, wherein said oligonucleotides have complementary 3′ ends.
8. A method for detection of a macromolecule, which comprises binding said macromolecule to a first affinity reagent having affinity for said macromolecule, said first affinity reagent being specific for a first determinant of said macromolecule;
incubating said first affinity reagent-bound macromolecule with said detection reagents of claim 1, specific for second and third determinants of said macromolecule, wherein said oligonucleotides conjugate to each other by hybridization or ligation when said detection reagents are both bound to said macromolecule;
amplifying said conjugated oligonucleotides; and
detecting the amplified products.
9. The method of claim 8, wherein said first affinity reagent is immobilized.
10. The method of claim 8, wherein said oligonucleotides conjugate through
i) hybridization of an oligonucleotide complementary to the conjugatable oligonucleotides;
ii) hybridization of the conjugatable oligonucleotides to each other; or
iii) ligation of the oligonucleotides.
11. The method according to claim 8, wherein the conjugation occurs through hybridization of an oligonucleotide complementary to the conjugatable oligonucleotides.
12. The method according to claim 8, wherein the conjuation occurs through hybridization of the conjugatable oligonucleotides to each other.
13. The method according to claim 11, wherein the conjugation occurs through ligation of the oligonucleotides.
14. The method claim 8, wherein said affinity reagents are antibodies.
15. The method of claim 8, wherein said affinity reagents are polyclonal antibodies, monoclonal antibodies or single chain antibodies.
  • [0001]
    The present invention relates to ultrasensitive immunoassays. More specifically, it relates to immunological test kits and processes for immunological detection of a specific antigen. In the present invention, the fields of immunology and molecular genetics are combined.
  • [0002]
    Immunoassays represent powerful tools to identify a very wide range of compounds, such as antigens and antibodies. Examples of immunoassays are ELISA (enzyme linked immunosorbent assay), EIA (enzyme immunoassay), and RIA (radio immunoassay). Common to all these immunoassays, is that detection sensitivity is limited by the affinity of typical antibodies.
  • [0003]
    With the prior art immunoassays, detection is not possible below a certain number of molecules, because the background, i.e. unspecifically bound material, interferes with the results. Detection of very low numbers of antigen is becoming increasingly important, especially for diagnostic applications. Therefore, further developments in sensitivity as well as specificity of immunological assays are desired.
  • [0004]
    Cantor et al, Science, Vol. 258, 2 Oct. 1992, have previously reported the attachment of oligonucleotides to antibodies in order to permit detection of such antibodies having bound antigen in immune reactions. A streptavidin-protein A chimera that posseses tight and specific binding affinity for both biotin and immunoglobulin G was used to attach biotinylated DNA specifically to antigen-monoclonal antibody complexes that had been immobilized on microtiter plate wells. Then, a segment of the attached DNA was amplified by PCR (Polymerase Chain Reaction). Analysis of the PCR products by agarose gel electrophoresis after staining with ethidium bromide allowed detection of 580 antigen molecules (9.610−22 moles) which is a significant improvement compared to, for example, conventional ELISA.
  • [0005]
    However, in Cantor et al., the labeled DNA-antibody complexes are assembled in situ during the assay. This can create variable stoichiometry in the assembly of the components and in the attachment of the DNA label. Moreover, extra steps are required for addition of biotinylated reagents and binding proteins. Numerous wash steps are also needed to remove excess reagents and to free assay components of non-specifically bound reagents.
  • [0006]
    Hendrickson et al., Nucleic Acids Research, 1995, Vol 23, No.3, report an advancement of the Cantor et al. assay that reduces complexity. This is achieved through labeling antibody with DNA by direct covalent linkage of the DNA to the antibody. In this approach, the analyte specific antibody and the 5′ amino modified DNA oligonucleotide are independently activated by means of separate heterobifunctional cross-linking agents. The activated antibody and DNA label are then coupled in a single spontaneous reaction.
  • [0007]
    International patent publication no. WO 91/17442 describes a molecular probe for use as a signal amplifier in immunoassays for detecting i.a. antigens. The probe comprises an antibody, a double stranded polynucleotide functioning as a promoter for a DNA dependend RNA polymerase, and a single or double stranded template for the promoter. The transcription product is quantified and correlated to the amount of present antigen in a sample.
  • [0008]
    However, in all three of the above described immunoassays the attached DNA is only used as a marker by being amplified to detectable levels. There is no distinction between oligonucleotides attached to antibodies having bound antigen and oligonucleotides attached to antibodies not having bound antigen, i.e. those being non-specifically trapped. Non-specifically trapped antibodies give rise to an undesired background signal and limits the minimun number of antigen molecules that can be detected and it will not be possible to distinguish between false positive and true positive results below a certain number of antigen molecules. Commonly, solid supports such as microtiter plates, are used for the reactions. According to prior art, there will always be an excess of oligonucleotide-labeled antibody that cannot be removed from the solid support by adding background-lowering agents and by repeated wash steps.
  • [0009]
    The present invention enables detection of extremely low numbers of antigenic molecules, even down to a single molecule. The invention provides reliable immunoassays in situations where insufficient numbers of antigens are available for conventional assays.
  • [0010]
    According to a first aspect of the invention, there is provided an immunological test kit comprising a first immobilized reagent having affinity for a specific macromolecule, such as a protein. Furthermore, the test kit comprises a second and a third affinity reagent specific for different determinantes of said macromolecule, and modified with crosslinkable compounds enabling a) conjugation of said second and third affinity reagent only when both are bound to the said, same macromolecule, and b) detection by amplification.
  • [0011]
    According to a preferred embodiment of the invention, the affinity reagents are antibodies and the crosslinkable compounds are oligonucleotide extensions attached to the second and third antibody, respectively. The macromolecule is in this case a specific antigen.
  • [0012]
    According to a second aspect of the invention there is provided an immundassay for detection of a specific antigen, comprising the following steps:
    • a) contacting a sample suspected of containing said specific antigen with a first antibody linked to a solid support, said first antibody being specific for a first epitope on the antigen,
    • b) washing off excess reagents,
    • c) incubating with a solution of a second and a third antibody specific for a second and third epitope of said antigen, and modified with crosslinkable oligonucleotides enabling conjugation of said second and third antibody when both are bound to the said, same antigen,
    • d) washing off excess reagents,
    • e) amplifying said crosslinked oligonucleotides, and
    • f) detecting the amplified products.
  • [0019]
    Products from the amplification reaction only result when two antibodies, i.e. the second and the third, have bound to the same antigen. Thus, amplification is specific for antibodies having bound to antigen. Non-specifically trapped antibodies do not give rise to any signal.
  • [0020]
    The present invention will be described more detailed below with reference to the accompanying drawings, in which
  • [0021]
    FIG. 1 is a schematic view of the principles of the immunoassay according to the invention, and
  • [0022]
    FIG. 2 shows chemical coupling of amino-modified oligonucleotides to macromolecules.
  • [0023]
    In FIG. 1 there is shown an immobilized antibody to a specific antigen applied together with two other antibodies, specific for other determinants on the same antigen. Besides antibodies other specifically interacting species with a known affinity, such as lectins, receptors, single chain antibodies, cofactors, oligonucleotides and other non-proteins, can be used in the invention.
  • [0024]
    The interacting species are modified with crosslinkable compounds in the form of an interacting pair, preferably short oligonucleotide extentions. Upon the coordinated binding of several so modified antibodies, oligonucleotides of neighbouring antibodies are conjugated to each other. The conjugation may or may not necessitate an enzymatic ligation step depending on the orientation of the oligonucleotide extensions.
  • [0025]
    If the conjugation is between free 3′ and 5′ ends ligation is necessary, such as by T4 RNA ligase or T4 DNA ligase. To facilitate the conjugation, it is convenient to use a stretch of oligonucleotides base pairing to and, thereby, juxtaposing the free ends of the oligonucleotides and permitting their joining through ligation.
  • [0026]
    If the conjugation is between free 3′ ends these have to be designed to be mutually complementary to achieve base pairing and initiation of DNA synthesis extending the 3′ ends of the the molecules.
  • [0027]
    Thus, only in those cases where the antibodies are brought close enough through binding to the same antigen molecule can the oligonucleotides be ligated. Ligated molecules subsequently serve as templates for nucleic acid amplification reactions.
  • [0028]
    In FIG. 2, there is shown a suitable way to attach the oligonucleotide extension to the antibodies. First, the oligonucleotides are terminally amino-modified and then attached to primary amines on the antibodies via disulphide bonds, e.g. according to the technique of Chue and Orgel, Nucleic Acid Research, Vol. 16, No. 9, 1988. Another way is by direct covalent coupling as described by Hendrickson et el., supra.
  • [0029]
    The antibodies used in the invention can be polyclonal, monoclonal or single chain antibodies produced by bacteriophages. In the latter case, it is possible to have antibodies equipped with an oligonucleotide binding part, rendering the above coupling step between antibody and oligonucleotide unnecessary.
  • [0030]
    The amplification technique to obtain detectable products is, for example, PCR (Polymerase Chain Reaction), LCR (Ligase Chain Reaction), SDA (Strand Displacement Amplification) bacteriophage Qβ replication, and 3SR (Self-Sustained Synthetic Reaction), of which the latter three methods do not require temperature cycling.
  • [0031]
    The method for detecting amplified products can, for example, be direct incorporation of a label, such as radioisotopes, fluorochromes, and enzymes, into the amplified products with the use of label-conjugated primers or nucleotides. Preferably, the accumulation of amplified products is monitored via the fluorescence from intercalating dyes, such as propidium iodide, etidium bromide and SYBR™ green from Molecular Probes.
  • [0032]
    The invention is not restricted to detection of any special kind of macromolecule, such as an antigen; the only criterion it has to fulfil is that it must be able to simultaneously bind three antibodies/affinity reagents. In the case where the affinity reagents are antibodies, the three antibodies are specific for different epitopes on the antigen. By biosensor analysis, it is possible to assure that the antibodies do not bind to overlapping epitopes on the antigen.
  • [0033]
    Examples of macromolecules are human myoglobin and human growth hormone. Ultrasensitive assays for growth hormone will have significant value in clinical situations where hormone levels are undetectable by prior art assays.
  • [0034]
    The invention will now be described below in a non-limiting Example.
  • [0035]
    Immunoglobulins were modified in a reaction with SPDP (3-(-pyridyldithio)propionic acid N-hydroxysuccinimide ester, from Pharmacia Biotech) according to the manufacturer's suggestions. Oligonucleotides were thiolated, either through the addition of a suitable phosphoramidite according to Connolly (Connolly B A, Nucl. Acid. Res. 1987 15:3131), or 3′aminomodified oligonucleotides were reacted with SPDP, followed by reduction of the dithiopyridyl bond, using dithiothreitol.
  • [0036]
    SPDP-modified antibodies were incubated with three equivalents of SH-containing oligonucleotides at 4 C. over night. The reaction mixture was separated using a Zorbax HPLC gel filtration column. Residual free antibody were removed from the isolated conjugate by ion exchange MonoQ FPLC separation.
  • [0037]
    The two oligonucleotides used to conjugate the antibodies were Oligo 1: 5′Tr S C3-ATA GAC TGA GCG TGG ACA TTA ATA TGT ACG TAG GCT TAA TTG AGT 3′ and Oligo 2: 5′P ATG TAC GAC CCG TAG ATA TTA TCA TAC TGG CAT GGG CAT GAT GAA CAT C-NHSPDP T3′
  • [0038]
    The immune test was performed by first binding 1 μg of biotinylated antibody (#1) to individual streptavidin-coated prongs on a manifold support. [Parik et al., Anal. Biochem; (1993) 211: 144-150B]. After washes using PBS (phosfhate buffered saline) with 0.5% Tween 20, the prongs were lowered into solutions of antigen (myoglobin) at variable concentrations. After further washes, the supports with bound antigen were incubated in a solution of two oligonucleotide-conjugated antibodies #2 and #3 at 5 ng each per reaction. The supports were washed, an oligonucleotide complementary to the free ends of the antibody-conjugated oligonucleotides was added (4 pmol per reaction, 540 CTA CGG GTC GTA CAT ACT CAA TTA AGC GTA 3′), and the ends of oligonucleotides on nearby antibodies were joined covalently by ligation at 37 C. for 30 min using 1 U of T4 DNA ligase. The supports were then washed in a standard PCR buffer, and the supports were added as templates in a PCR mix, including two primers specific for sequences located at either side of the ligation junction (5′TTA ATG GCG AG 3′) and Taq polymerase. After two cycles, the supports were removed and the amplification was continued for 26 more cycles. Amplification products were examined by separation in an agarose gel and ethidium bromide staining.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2079172 *28 Feb 19344 May 1937Chandler & Price CoPlaten printing press
US4563417 *24 Dec 19847 Jan 1986Miles Laboratories, Inc.Nucleic acid hybridization assay employing antibodies to intercalation complexes
US4690890 *4 Apr 19841 Sep 1987Cetus CorporationProcess for simultaneously detecting multiple antigens using dual sandwich immunometric assay
US4748111 *12 Mar 198431 May 1988Molecular Diagnostics, Inc.Nucleic acid-protein conjugate used in immunoassay
US4824775 *3 Jan 198525 Apr 1989Molecular Diagnostics, Inc.Cells labeled with multiple Fluorophores bound to a nucleic acid carrier
US4988617 *25 Mar 198829 Jan 1991California Institute Of TechnologyMethod of detecting a nucleotide change in nucleic acids
US5011771 *24 Sep 198730 Apr 1991The General Hospital CorporationMultiepitopic immunometric assay
US5026653 *30 Sep 198725 Jun 1991Leeco Diagnostic, Inc.Scavenger antibody mixture and its use for immunometric assay
US5219734 *13 Jan 198815 Jun 1993Amoco CorporationTemplate-directed photoligation
US5384255 *21 Jun 199324 Jan 1995Rappaport Family Institute For Research In The Medical SciencesUbiquitin carrier enzyme E2-F1, purification, production, and use
US5415839 *21 Oct 199316 May 1995Abbott LaboratoriesApparatus and method for amplifying and detecting target nucleic acids
US5635602 *13 Aug 19933 Jun 1997The Regents Of The University Of CaliforniaDesign and synthesis of bispecific DNA-antibody conjugates
US5652107 *15 Jul 199629 Jul 1997The Public Health Research Institute Of The City Of New York, Inc.Diagnostic assays and kits for RNA using RNA binary probes and a ribozyme ligase
US5656731 *1 Jul 199312 Aug 1997Chiron CorporationNucleic acid-amplified immunoassay probes
US5667974 *7 Jun 199516 Sep 1997Abbott LaboratoriesMethod for detecting nucleic acid sequences using competitive amplification
US5693764 *18 Apr 19962 Dec 1997The University Of Kentucky Research FoundationNucleotide or nucleoside photoaffinity compound modified antibodies, methods for their manufacture and use thereof as diagnostics and therapeutics
US5759773 *24 Feb 19952 Jun 1998The Public Health Research Institute Of The City Of New York, Inc.Sensitive nucleic acid sandwich hybridization assay
US5780231 *5 Mar 199614 Jul 1998Lynx Therapeutics, Inc.DNA extension and analysis with rolling primers
US5804384 *6 Dec 19968 Sep 1998Vysis, Inc.Devices and methods for detecting multiple analytes in samples
US5812272 *30 Jan 199722 Sep 1998Hewlett-Packard CompanyApparatus and method with tiled light source array for integrated assay sensing
US5814492 *13 Aug 199729 Sep 1998Abbott LaboratoriesProbe masking method of reducing background in an amplification reaction
US5830670 *30 May 19953 Nov 1998The General Hospital CorporationNeural thread protein gene expression and detection of Alzheimer's disease
US5849878 *7 Jun 199515 Dec 1998The Regents Of The University Of CaliforniaDesign and synthesis of bispecific reagents: use of double stranded DNAs as chemically and spatially defined cross-linkers
US5876976 *23 Jan 19952 Mar 1999Amgen Inc.Method for reducing carryover contamination in an amplification procedure
US5919626 *6 Jun 19976 Jul 1999Orchid Bio Computer, Inc.Attachment of unmodified nucleic acids to silanized solid phase surfaces
US5962223 *19 Dec 19955 Oct 1999The Perkin-Elmer CorporationDetection of specific sequences in nucleic acids
US5985548 *4 Feb 199316 Nov 1999E. I. Du Pont De Nemours And CompanyAmplification of assay reporters by nucleic acid replication
US6143508 *7 Jun 19957 Nov 2000Rhone-Poulenc Rorer Pharmaceuticals Inc.Device and process for cell capture and recovery
US6235472 *18 Jun 199822 May 2001Ulf LandegrenNucleic acid detecting reagent
US6511809 *16 May 200128 Jan 2003E. I. Du Pont De Nemours And CompanyMethod for the detection of an analyte by means of a nucleic acid reporter
US6558928 *25 Mar 19996 May 2003Ulf LandegrenRolling circle replication of padlock probes
US6878515 *14 Jun 199612 Apr 2005Ulf LandegrenUltrasensitive immunoassays
US7074564 *6 May 200311 Jul 2006Ulf LandegrenRolling circle replication of padlock probes
US20020051986 *16 May 20012 May 2002Luis BaezMethod for the detection of an analyte by means of a nucleic acid reporter
US20020064779 *20 Feb 200130 May 2002Ulf LandegrenMethods and kits for proximity probing
US20030148335 *10 Oct 20027 Aug 2003Li ShenDetecting targets by unique identifier nucleotide tags
US20030207300 *7 Jan 20036 Nov 2003Matray Tracy J.Multiplex analytical platform using molecular tags
US20040038200 *11 Jul 200126 Feb 2004Wilson Stuart MarkDistinguishing molecular forms
US20040234966 *23 May 200325 Nov 2004Applera CorporationIonic liquid apparatus and method for biological samples
US20050009050 *19 Apr 200413 Jan 2005James NadeauImmuno-amplification
US20050287528 *4 Apr 200329 Dec 2005Mount Sinai HospitalMethods for detecting ovarian cancer
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US79023454 Jun 20088 Mar 2011Sequenom, Inc.Detection and quantification of biomolecules using mass spectrometry
US81337014 Dec 200713 Mar 2012Sequenom, Inc.Detection and quantification of biomolecules using mass spectrometry
US83837953 Mar 201126 Feb 2013Sequenom, Inc.Detection and quantification of biomolecules using mass spectrometry
US905160813 Feb 20139 Jun 2015Agena Bioscience, Inc.Detection and quantification of biomolecules using mass spectrometry
US940415028 Aug 20082 Aug 2016Sequenom, Inc.Methods and compositions for universal size-specific PCR
US20080305479 *4 Dec 200711 Dec 2008Sequenom, Inc.Detection and quantification of biomolecules using mass spectrometry
US20090111712 *4 Jun 200830 Apr 2009Sequenom, Inc.Detection and quantification of biomolecules using mass spectrometry
US20110160093 *3 Mar 201130 Jun 2011Sequenom, Inc.Detection and quantification of biomolecules using mass spectrometry
CN103454427A *3 Jun 201218 Dec 2013河北省健海生物芯片技术有限责任公司Method for detecting trace protein in blood by utilizing antibody-nucleic acid combined amplification technology
WO2014210376A1 *26 Jun 201431 Dec 2014The Board Of Trustees Of The Leland Stanford Junior UniversityDna-conjugated antibodies for improved antibody affinity and reduced antibody cross reactivity
U.S. Classification435/6.11, 435/7.1
International ClassificationG01N33/543, C12Q1/68, G01N33/532
Cooperative ClassificationY10S435/975, Y10S435/81, C12Q1/682, C12Q1/6816, G01N33/54306
European ClassificationG01N33/543B, C12Q1/68B2, C12Q1/68B2D